REG - IQ-AI Limited - IQ-AI Prepares for Phase I Clinical Trial Launch

IQ-AIAnnouncement

17/12/2021 07:40

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211217:nRSQ0182Wa&default-theme=true

RNS Number : 0182W  IQ-AI Limited  17 December 2021

17 December 2021

IQ-AI LIMITED

("IQ-AI" or the "Company")

IQ-AI Prepares for Phase I Clinical Trial Launch

IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI),

IQ-AI has been working with the clinical team at the Medical College of
Wisconsin (MCW) to qualify a new supplier for encapsulating the drug
candidate. The Company is pleased to announce that a supplier has been
contracted and the production of the capsules is now underway. IQ-AI
anticipates the trial will commence in February 2022.

While the qualification of a new supplier imposed a delay to the start of the
trial, a robust source of supply is now ready to provide an efficient and
continuous distribution of capsules to enrolled patients for this Phase I as
well as subsequent trials.

"We appreciate everyone's efforts to secure an alternative encapsulation
supplier for oral GaM and now await the start of this clinical trial," said
Trevor Brown, CEO of IQ-AI.

The Directors of the Company accept responsibility for the contents of this
announcement.

 

- ENDS-

 

For further information, please contact:

 

 IQ-AI Limited

 Trevor Brown/Brett Skelly/Vinod Kaushal

 Tel: 020 7469 0930

 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law
(as defined in the European Union (Withdrawal) Act 2018).

 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Imaging
Biometrics, LLC (IB), develops and provides visualisation and analytical
solutions that enable clinicians to better diagnose and treat disease with
greater confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can extend the base
functionality of workstations, imaging systems, PACS, or medical viewers. By
design, IB's advanced visualisation software seamlessly integrates into
routine workflows. For more information about Imaging Biometrics, visit the
company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUBOBRANUUARA